<b>Come join others currently navigating treatment</b> in our weekly Virtual Support Groups! <a href="https://www.breastcancer.org/community/virtual-meetups#section-in-treatment-for-breast-cancer">See times and register here.</a>
<b>We need your inspirational words for a new project!</b> <a href="https://community.breastcancer.org/en/discussion/888451/we-need-your-inspirational-words-partnership-with-uncommon-goods">Share with us.</a>
Podcast: AIs vs. Tamoxifen for Pre-Menopausal Early-Stage, HR+
moderators
Posts: 10,599
December 13, 2021
Dr. Jeremy Braybrooke, is a consultant medical oncologist and clinical lead for oncology at University Hospitals Bristol, as well as a senior clinical research fellow at the University of Oxford. Rosie Bradley is a medical statistician in the Clinical Trial Service Unit at the University of Oxford.
At the 2021 San Antonio Breast Cancer Symposium, Rosie presented the results of their meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen in pre-menopausal women diagnosed with early-stage, hormone receptor-positive disease.
Listen to the episode to hear them explain:
- the results of the study, showing that an aromatase inhibitor and ovarian suppression reduced recurrence risk more than tamoxifen, but didn't lead to better overall survival
- the side effects of aromatase inhibitors and tamoxifen
- how Dr. Braybrooke is advising his pre-menopausal patients diagnosed with early-stage, hormone receptor-positive disease
Running time: 14:19
Listen now or read the transcript.0
Categories
<b>Join Us on Zoom:</b> Upcoming virtual support groups. <a href="https://www.breastcancer.org/community/virtual-meetups"</a> Read more...</a>
<b>Share more about you!</b> <a href="https://community.breastcancer.org/en/profile/edit-fields?utm_source=forums&utm_medium=message-2&utm_campaign=new-profile">Fill out your profile.</a>